Richard J. Lin MD PhD

HCT/cellular therapy specialist @MSKCancerCenter via @nyulangone @BellevueHosp @Harvardmed @WeillCornell #aging #gerionc #supportivecare Tweets/RT my own.

[MSK Department of Medicine @MSK_DeptOfMed]

Join @DrRichardJLin today at #ASH25 to learn about methods for preventing and treating age-related blood conditions, including #exercise, #nutrition, new therapies, and more. @MSKCancerCenter @ASH_hematology

Learn more: https://t.co/gWoJIMS9Gz

[Yi Lin @YiLinMDPhD]

Can we improve #CART by targeting senescence? Come to the scientific workshop this afternoon #ASH2025 @DrRichardJLin @MegVoda @MayoCancerCare @nadineabdal @VincentRK @Leif_Bergsagel

[Pashna N. Munshi MD @MunshiPashnaMD]

US Geriatric Assessment Practices for Older Adults Undergoing Hematopo... https://t.co/ocZ7uumqC9
In a first of its kind team effort with a so grateful for the commitment and mentorship by all! @MediHumdani,Andy Artz, Paul Carpenter @ASTCT improving our survey methodologies🤞🏼

[Earth_Wanderer @earth_tracker]

Places on Earth that look too magical to be real🧵

1. Trollstigen, Norway 🇳🇴

[MSK Department of Medicine @MSK_DeptOfMed]

New research from @MSKCancerCenter takes a step toward off-the-shelf CAR T cell therapy for #cancer. Author Karlo Perica explains his and Michel Sadelain's recent study in @Nature that demonstrated cells from healthy donors can be stored for future use. https://t.co/hk4tBDeQAX

[Shernan Holtan MD @sghmd]

I'm concerned that the recent @statnews piece re: decline of #BMT by @angRchen could be misleading to the public. Adding some context for consideration in the thread 🧵below: https://t.co/A2VBjwyWiB

[Samuel Hume @DrSamuelBHume]

2024's top 10 advances in biology (🧵)

1. Progress in longevity

Blocking the pro-inflammatory cytokine, IL11, extended healthspan and lifespan (in mice!)

Old mice without IL11 look healthier, they're stronger, and they live longer

https://t.co/Y0Raog12xk

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Presentation alert: @DrRichardJLin will share his research on advanced myeloid malignancies at @ASH_hematology later today. #ASH24

[Nina Rosa Neuendorff @neuendorff_nr]

Thanks to @JGeriOnc for highlighting our paper as paper of the month! @SamuelJYates @fa_ulle @Ashley_Rosko1 @DrRaulCordoba @AMoKhanMD @DrRichardJLin

[Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO @tomleblancMD]

Fascinating new study shows that patients with chronic pain who are cared for by more empathic physicians have better outcomes, not just in pain scores but also function and quality of life. #hapc #pallonc https://t.co/AX2yL4Pz0u

[Brian Shaffer @BrianShafferMD]

⁦@Karthik_Nath17⁩ giving a fine presentation on our work comparing older siblings to younger matched URDs when PTCy is used. Younger URDs improved disease free survival compared to older siblings. Manuscript coming!

[Benlazar S M A @smbenlazar]

Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial - https://t.co/UCIWB316au #leusm #AML

[L. Elizabeth Budde, M.D., Ph.D. @elizabeth_budde]

We reported the longest follow up of using BsAbs in lymphoma. With a median 3.5 years f/u, the DOCR for patients treated with mosunetuzumab is not reached. No relapses post 26 months. Retreatment worked in 10/12 including 7 CRs.
https://t.co/TRnSrwzNVa

[Sarah Wall, MD MPH @SarahAllison10]

#Tandem24 Aging SIG Poster Walk Saturday at Noon - begins at Poster 593 - Tell your friends! @JayaniReena @AndrewArtz @ROlinMD @MunshiPashnaMD @DrRichardJLin @Ashley_Rosko1 @HKlepinMD @tanyawildes @ASTCT

[Talha Badar @TalhaBadarMD]

Weekend review 📖

What is the right duration of VENETOCLAX with HMA for AML: 7 days vs 14 days vs 21 days or 28 days?

Brief review of literature in this 🧵

#leusm #AML

[Richard J. Lin MD PhD @DrRichardJLin]

@drkomanduri @ElenaMeloni9 Correct! A marvelous place!

[Richard J. Lin MD PhD @DrRichardJLin]

Guess where I am on vacation?
Bonus: name this Basillica

[Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO @tomleblancMD]

Our multisite RCT of integrated specialist #palliativecare in 360 pts undergoing stem cell transplantation demonstrates the superiority of this care model. Very proud to be part of this practice changing study, led by @Areejmd, w/ @JasAWebb and @StephanieLeeMD #ash23 #hapc

[Mehdi Hamadani, MD @MediHumdani]

If you see an eligible DLBCL patient in CR, does #CART outperform AutoHCT? Only available data by @CIBMTR @mshadman Reminds you to keep an open mind,
one size does not fit all 🙏🙏 @ASH_hematology for recognizing our work in Press Release #ASH23

[Raul Cordoba, MD, PhD #EHA2026 @DrRaulCordoba]

Cost-Utility Analysis of Geriatric Assessment and Management in Older Adults With #Cancer: Economic Evaluation Within 5C Trial | Journal of Clinical Oncology ⁦@JCO_ASCO⁩ #gerionc #geriheme https://t.co/Bt0xEQy3vA